YM155, a survivin suppressant, triggers PARP-dependent cell death (parthanatos) and inhibits esophageal squamous-cell carcinoma xenografts in mice

Oncotarget

Volumn 6, Issue 21, 2015, Pages 18445-18459

  Zhao, Nan ^a   Mao, Yousheng ^a   Han, Gaijing ^a   Ju, Qiang ^a   Zhou, Lanping ^a   Liu, Fang ^a   Xu, Yang ^a   Zhao, Xiaohang ^a  

^a CANCER HOSPITAL   (China)

Author keywords

Chemotherapy; Esophageal cancer; PARP; Parthanatos

Indexed keywords

MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN C FOS; PROTEIN C JUN; SEPANTRONIUM BROMIDE; SURVIVIN; BIRC5 PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; INHIBITOR OF APOPTOSIS PROTEIN; NAPHTHOQUINONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL DEATH; CELL NUCLEUS; CONTROLLED STUDY; CYTOSOL; DRUG EFFECT; DRUG STRUCTURE; EMBRYO; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE SILENCING; GENETIC TRANSCRIPTION; MOUSE; NONHUMAN; ONCOGENE C FOS; ONCOGENE C JUN; ONCOGENE C MYC; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, SQUAMOUS CELL; CELL SURVIVAL; DNA MICROARRAY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; ESOPHAGEAL NEOPLASMS; FLUORESCENCE MICROSCOPY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; NUDE MOUSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL LINE; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; INHIBITOR OF APOPTOSIS PROTEINS; MICE, NUDE; MICROSCOPY, ELECTRON, TRANSMISSION; MICROSCOPY, FLUORESCENCE; NAPHTHOQUINONES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLY(ADP-RIBOSE) POLYMERASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84938808932     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4315     Document Type: Article

References (51)

1. Zhu H, Wang Q, Hu C, Zhang W, Quan L, Liu M, et al. High expression of survivin predicts poor prognosis in esophageal squamous cell carcinoma following radiotherapy. Tumour Biol. 2011; 32:1147-53.
2. Rosato A, Pivetta M, Parenti A, Iaderosa GA, Zoso A, Milan G, et al. Survivin in esophageal cancer: An accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma. Int J Cancer. 2006; 119:1717-22.
3. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2008; 8:61-70.
4. Dabrowski A, Filip A, Zgodzinski W, Dabrowska M, Polanska D, Wojcik M, et al. Assessment of prognostic significance of cytoplasmic survivin expression in advanced oesophageal cancer. Folia Histochem Cytobiol. 2004; 42:169-72.
5. Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 2007; 67:8014-21.
6. Chen J, Pise-Masison CA, Shih JH, Morris JC, Janik JE, Conlon KC, et al. Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia. Blood. 2013; 121:2029-37.
7. Mir R, Stanzani E, Martinez-Soler F, Villanueva A, Vidal A, Condom E, et al. YM155 sensitizes ovarian cancer cells to cisplatin inducing apoptosis and tumor regression. Gynecol Oncol. 2014; 132:211-20.
8. Koike H, Nitta T, Sekine Y, Arai S, Furuya Y, Nomura M, et al. YM155 reverses rapamycin resistance in renal cancer by decreasing survivin. J Cancer Res Clin Oncol. 2014;140:1705-13.
9. Nakamura N, Yamauchi T, Hiramoto M, Yuri M, Naito M, Takeuchi M, et al. Interleukin enhancer-binding factor 3/NF110 is a target of YM155, a suppressant of survivin. Mol Cell Proteomics. 2012; 11: M111 013243.
10. Kasap C, Elemento O, Kapoor TM. DrugTargetSeqR: a genomics- and CRISPR-Cas9-based method to analyze drug targets. Nat Chem Biol. 2014; 10:626-8.
11. Zhao P, Dai M, Chen W, Li N. Cancer trends in China. Jpn J Clin Oncol. 2010; 40:281-5.
12. Wei WQ, Yang J, Zhang SW, Chen WQ, Qiao YL. Esophageal cancer mortality trends during the last 30 years in high risk areas in China: comparison of results from national death surveys conducted in the 1970's, 1990's and 2004-2005. Asian Pac J Cancer Prev. 2011; 12:1821-6.
13. Ilson DH. Esophageal cancer chemotherapy: recent advances. Gastrointest Cancer Res. 2008; 2:85-92.
14. Wu C, Li D, Jia W, Hu Z, Zhou Y, Yu D, et al. Genomewide association study identifies common variants in SLC39A6 associated with length of survival in esophageal squamous-cell carcinoma. Nat Genet. 2013; 45:632-8.
15. Shimada Y, Imamura M, Wagata T, Yamaguchi N, Tobe T. Characterization of 21 newly established esophageal cancer cell lines. Cancer. 1992; 69:277-84.
16. Xu Y, Lin Z, Zhao N, Zhou L, Liu F, Cichacz Z, et al. Receptor interactive protein kinase 3 promotes Cisplatintriggered necrosis in apoptosis-resistant esophageal squamous cell carcinoma cells. PLoS One. 2014; 9:e100127.
17. Xu Y, Zhou L, Huang J, Liu F, Yu J, Zhan Q, et al. Role of Smac in determining the chemotherapeutic response of esophageal squamous cell carcinoma. Clin Cancer Res. 2011; 17:5412-22.
18. Han B, Li W, Sun Y, Zhou L, Xu Y, Zhao X. A prolylhydroxylase inhibitor, ethyl-3, 4-dihydroxybenzoate, induces cell autophagy and apoptosis in esophageal squamous cell carcinoma cells via up-regulation of BNIP3 and N-myc down-stream-regulated gene-1. PLoS One. 2014; 9:e107204.
19. Irizarry RA, Ooi SL, Wu Z, Boeke JD. Use of mixture models in a microarray-based screening procedure for detecting differentially represented yeast mutants. Stat Appl Genet Mol Biol. 2003; 2. Article1.
20. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4:44-57.
21. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2014;43:D447-52.
22. Winter GE, Radic B, Mayor-Ruiz C, Blomen VA, Trefzer C, Kandasamy RK, et al. The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity. Nat Chem Biol. 2014; 10:768-73.
23. Feng W, Yoshida A, Ueda T. YM155 induces caspase-8 dependent apoptosis through downregulation of survivin and Mcl-1 in human leukemia cells. Biochem Biophys Res Commun. 2013; 435:52-7.
24. Wang YF, Zhang W, He KF, Liu B, Zhang L, Zhang WF, et al. Induction of autophagy-dependent cell death by the survivin suppressant YM155 in salivary adenoid cystic carcinoma. Apoptosis. 2014; 19:748-58.
25. Zilio N, Williamson CT, Eustermann S, Shah R, West SC, Neuhaus D, et al. DNA-dependent SUMO modification of PARP-1. DNA Repair (Amst). 2013; 12:761-73.
26. Metzger MJ, Stoddard BL, Monnat RJ Jr. PARP-mediated repair, homologous recombination, and back-up nonhomologous end joining-like repair of single-strand nicks. DNA Repair (Amst). 2013; 12:529-34.
27. Chiu LY, Ho FM, Shiah SG, Chang Y, Lin WW. Oxidative stress initiates DNA damager MNNG-induced poly(ADP-ribose) polymerase-1-dependent parthanatos cell death. Biochem Pharmacol. 2011; 81:459-70.
28. Andrabi SA, Dawson TM, Dawson VL. Mitochondrial and nuclear cross talk in cell death: parthanatos. Ann N Y Acad Sci. 2008; 1147:233-41.
29. David KK, Andrabi SA, Dawson TM, Dawson VL. Parthanatos, a messenger of death. Front Biosci (Landmark Ed). 2009; 14:1116-28.
30. Yu SW, Wang H, Poitras MF, Coombs C, Bowers WJ, Federoff HJ, et al. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science. 2002; 297:259-63.
31. Lee Y, Karuppagounder SS, Shin JH, Lee YI, Ko HS, Swing D, et al. Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss. Nat Neurosci. 2013; 16:1392-400.
32. Mostocotto C, Carbone M, Battistelli C, Ciotti A, Amati P, Maione R. Poly(ADP-ribosyl)ation is required to modulate chromatin changes at c-MYC promoter during emergence from quiescence. PLoS One. 2014; 9:e102575.
33. Yang L, Huang K, Li X, Du M, Kang X, Luo X, et al. Identification of poly(ADP-ribose) polymerase-1 as a cell cycle regulator through modulating Sp1 mediated transcription in human hepatoma cells. PLoS One. 2013; 8:e82872.
34. Yamanaka K, Nakahara T, Yamauchi T, Kita A, Takeuchi M, Kiyonaga F, et al. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models. Clin Cancer Res. 2011; 17:5423-31.
35. Kita A, Nakahara T, Yamanaka K, Nakano K, Nakata M, Mori M, et al. Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma. Leuk Res. 2011; 35:787-92.
36. Yamauchi T, Nakamura N, Hiramoto M, Yuri M, Yokota H, Naitou M, et al. Sepantronium bromide (YM155) induces disruption of the ILF3/p54(nrb) complex, which is required for survivin expression. Biochem Biophys Res Commun. 2012; 425:711-6.
37. Cheng Q, Ling X, Haller A, Nakahara T, Yamanaka K, Kita A, et al. Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter. Int J Biochem Mol Biol. 2012; 3:179-97.
38. Glaros TG, Stockwin LH, Mullendore ME, Smith B, Morrison BL, Newton DL. The "survivin suppressants" NSC 80467 and YM155 induce a DNA damage response. Cancer Chemother Pharmacol. 2012; 70:207-12.
39. Wang Y, Dawson VL, Dawson TM. Poly(ADP-ribose) signals to mitochondrial AIF: a key event in parthanatos. Exp Neurol. 2009; 218:193-202.
40. Akhiani AA, Werlenius O, Aurelius J, Movitz C, Martner A, Hellstrand K, et al. Role of the ERK pathway for oxidant-induced parthanatos in human lymphocytes. PLoS One. 2014; 9:e89646.
41. Jeggo PA. DNA repair: PARP - another guardian angel? Curr Biol. 1998; 8:R49-51.
42. Spina-Purrello V, Patti D, Giuffrida-Stella AM, Nicoletti VG. Parp and cell death or protection in rat primary astroglial cell cultures under LPS/IFNgamma induced proinflammatory conditions. Neurochem Res. 2008; 33:2583-92.
43. Huang CT, Huang DY, Hu CJ, Wu D, Lin WW. Energy adaptive response during parthanatos is enhanced by PD98059 and involves mitochondrial function but not autophagy induction. Biochim Biophys Acta. 2014; 1843:531-43.
44. Donizy P, Halon A, Surowiak P, Pietrzyk G, Kozyra C, Matkowski R. Correlation between PARP-1 immunoreactivity and cytomorphological features of parthanatos, a specific cellular death in breast cancer cells. Eur J Histochem. 2013; 57:e35.
45. Kuzhandaivel A, Nistri A, Mladinic M. Kainate-mediated excitotoxicity induces neuronal death in the rat spinal cord in vitro via a PARP-1 dependent cell death pathway (Parthanatos). Cell Mol Neurobiol. 2010; 30:1001-12.
46. Ha HC, Snyder SH. Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc Natl Acad Sci U S A. 1999; 96:13978-82.
47. Andrabi SA, Kim NS, Yu SW, Wang H, Koh DW, Sasaki M, et al. Poly(ADP-ribose) (PAR) polymer is a death signal. Proc Natl Acad Sci U S A. 2006; 103:18308-13.
48. Yu SW, Andrabi SA, Wang H, Kim NS, Poirier GG, Dawson TM, et al. Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. Proc Natl Acad Sci U S A. 2006; 103:18314-9.
49. Seillier M, Peuget S, Gayet O, Gauthier C, N'Guessan P, Monte M, et al. TP53INP1, a tumor suppressor, interacts with LC3 and ATG8-family proteins through the LC3-interacting region (LIR) and promotes autophagy-dependent cell death. Cell Death Differ. 2012; 19:1525-35.
50. Carbone M, Rossi MN, Cavaldesi M, Notari A, Amati P, Maione R. Poly(ADP-ribosyl)ation is implicated in the G0-G1 transition of resting cells. Oncogene. 2008; 27:6083-92.
51. Caiafa P, Guastafierro T, Zampieri M. Epigenetics: poly(ADP-ribosyl)ation of PARP-1 regulates genomic methylation patterns. FASEB J. 2009; 23:672-8.